Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment.

Isabelle Danika GauthierChad Arthur MacleodPaul SathiadossTrevor Adam McGrathVimoj NairNicola Schieda

Published in: Abdominal radiology (New York) (2022)

No cases of NSF were documented in this study related to gadoxetic acid use in oncology patients, including those with moderate and severe renal impairment. Recent data indicate use of gadoxetic acid in patients with renal impairment can be considered low-risk.

Keyphrases

diffusion weighted imaging
palliative care
ejection fraction
end stage renal disease
newly diagnosed
early onset
high intensity
magnetic resonance
prognostic factors
electronic health record